Canaccord Genuity on Life Sciences/Biomedical Devices and Services: Take on Q4 and Beyond

Canaccord Genuity on Life Sciences/Biomedical Devices and Services: Dynamics of the diabetes industry into 2012: our take on Q4/11 and beyond

Analyst, William J. Plovanic, said, "Heading into the Q4/11 earnings season for diabetes technology and wound care, we remain long-term buyers of DexCom (Nasdaq: DXCM)(BUY), Insulet (Nasdaq: PODD)(BUY) and Derma Sciences (Nasdaq: DSCI)(BUY). However, we note that broader economic headwinds related to the decline in consumer confidence and high unemployment levels, in addition to patients working through higher insurance costs, may depress industry growth in the near term. Additionally, the broader wound care market is relatively insulated to economic pressures due to the non-discretionary nature of chronic wounds, and Derma Sciences is well positioned due to its differentiated advanced wound care portfolio and new product cycle."

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
• Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS